XML 51 R38.htm IDEA: XBRL DOCUMENT v3.21.2
License and Collaboration Agreements - Narrative (Details)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended 84 Months Ended
May 28, 2021
USD ($)
Aug. 03, 2020
shares
Jan. 07, 2018
USD ($)
Oct. 31, 2014
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Mar. 31, 2018
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Dec. 31, 2020
USD ($)
Sep. 30, 2021
USD ($)
Oct. 01, 2014
USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Revenue recognized         $ 71,793,000 $ 11,424,000   $ 71,793,000 $ 11,690,000      
Expenses related to collaboration agreement         116,109,000 79,853,000   354,755,000 216,644,000      
Income tax expense         3,299,000 0   3,299,000 0      
Milestone Payments                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Expenses related to collaboration agreement                 4,800,000      
BeiGene Agreement                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Up-front fee received     $ 10,000,000                  
Revenue from performance obligation expected to be earned     $ 123,000,000                  
Termination of contract, period after first commercial sale of product     10 years                  
Period required for notice of termination of contract     60 days                  
BeiGene Agreement | Maximum                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Royalty percentage rate (up to)     0.20                  
BeiGene Agreement | Licenses of Intellectual Property                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Performance obligation, compensation to be earned             $ 9,500,000          
BeiGene Agreement | Manufacturing Supply Services                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Performance obligation, compensation to be earned                   $ 500,000    
Revenue recognized         100,000 0   100,000 300,000      
BeiGene Agreement | Milestone Payments                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Milestone payments earned         5,000,000 0   5,000,000 0      
BeiGene Agreement | Royalties                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Royalty revenue         0 0   0 0      
Pfizer Agreement                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Termination of contract, period after first commercial sale of product       10 years                
Period required for notice of termination of contract       60 days                
Expenses related to collaboration agreement         0              
Pfizer Agreement | adagrasib                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Expenses related to collaboration agreement               5,000,000        
Pfizer Agreement | Milestone Payments | MRTX1133                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Expenses related to collaboration agreement           $ 300,000     300,000      
Pfizer Agreement | Milestone Payments | adagrasib                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Expenses related to collaboration agreement                 3,000,000      
Pfizer Agreement | Development Milestone Payments                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Milestone payments payable                       $ 9,300,000
Milestone payments paid since inception                     $ 9,500,000  
Pfizer Agreement | Sales Milestone Payments                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Milestone payments payable                       $ 337,000,000
Pfizer Agreement | Research and Development Services                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Expenses related to collaboration agreement                 $ 1,500,000      
ORIC Pharmaceuticals Agreement                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Stock received as part of stock issuance and license agreements (shares) | shares   588,235                    
License agreement, period of transfer restrictions   18 months                    
License agreement, period of agreement after first commercial sale   10 years                    
Zai Agreement                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Up-front fee received $ 65,000,000                      
Period required for notice of termination of contract 12 months                      
Transaction price of arrangement $ 66,600,000                      
Termination of contract, period after first commercial sale of product 10 years                      
Zai Agreement | Licenses of Intellectual Property                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Revenue recognized         66,600,000              
Income tax expense         3,300,000              
Zai Agreement | Manufacturing Supply Services                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Revenue recognized         0     0        
Zai Agreement | Sales Milestone Payments                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Revenue from performance obligation expected to be earned $ 180,000,000                      
Zai Agreement | Development and Regulatory Milestone Payments                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Revenue from performance obligation expected to be earned $ 93,000,000                      
Zai Agreement | Royalties                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Royalty revenue         $ 0     $ 0